中药概念持续拉升，万邦德涨停，康芝药业、天目药业、珍宝岛、吉林敖东等跟涨。 ...

Core Viewpoint - The Chinese medicine sector experienced a slight increase of 0.51% on October 9, with Zhenbaodao leading the gains. The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1]. Group 1: Stock Performance - Zhenbaodao (603567) closed at 11.60, with a rise of 4.50% and a trading volume of 135,100 shares, amounting to a transaction value of 156 million yuan [1]. - Mayinglong (600993) closed at 27.01, increasing by 2.12% with a trading volume of 79,600 shares, resulting in a transaction value of 214 million yuan [1]. - Yiling Pharmaceutical (002603) closed at 16.20, up 1.95% with a trading volume of 166,000 shares, totaling 267 million yuan in transaction value [1]. - Wanbangde (002082) closed at 12.21, rising by 1.83% with a trading volume of 314,300 shares, leading to a transaction value of 380 million yuan [1]. - Qidi Pharmaceutical (000590) closed at 11.69, increasing by 1.83% with a trading volume of 57,800 shares, amounting to 66.27 million yuan [1]. Group 2: Capital Flow - The Chinese medicine sector saw a net outflow of 247 million yuan from institutional investors, while retail investors contributed a net inflow of 134 million yuan [2]. - The main capital inflow was observed in Jilin Aodong (000623) with a net inflow of 30.13 million yuan, representing 6.33% of the total [3]. - Mayinglong (600993) experienced a net inflow of 23.70 million yuan from main capital, accounting for 11.10% [3]. - Renhe Pharmaceutical (000650) had a net inflow of 23.10 million yuan, making up 13.72% of the total [3]. - Wanbangde (002082) saw a net inflow of 17.28 million yuan from main capital, which is 4.54% [3].

Core Points - The Shanghai Composite Index is currently at 3913.21 points, above the annual line, with a change of 0.78% [1] - The total trading volume of A-shares today is 1,302.057 billion yuan [1] - A total of 55 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates [1] Summary of Key Stocks - Tianli Composite (证券代: 920576) has a price increase of 12.86% and a deviation rate of 11.43% [1] - China General Nuclear Power Technology (证券代: 000881) has a price increase of 6.55% and a deviation rate of 5.45% [1] - Baoland (证券代: 688058) has a price increase of 6.14% and a deviation rate of 4.86% [1] - Other stocks with notable performance include Chenguang Medical (证券代: 920300) with a 5.57% increase and a 2.94% deviation rate, and Sunlight Energy (证券代: 000591) with a 3.08% increase and a 2.71% deviation rate [1] Additional Stocks with Minor Deviations - Stocks like Xiamen International Trade (证券代: 000155) and Guizhou Wheel Tire (证券代: 000589) have minor deviations of 1.14% and 0.96% respectively, indicating they have just crossed the annual line [2]

Company Overview - Zhenbaodao Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, established on October 28, 1996, and listed on April 24, 2015. The company focuses on the research, production, and sales of high-end traditional Chinese medicine formulations, with a diverse range of dosage forms and products [2]. Financial Performance - For the first half of 2025, Zhenbaodao reported operating revenue of 714 million yuan, a year-on-year decrease of 57.05%. The net profit attributable to the parent company was -78.29 million yuan, reflecting a year-on-year decline of 119.90% [2]. - Since its A-share listing, Zhenbaodao has distributed a total of 1.302 billion yuan in dividends, with 356 million yuan distributed over the past three years [3]. Stock Performance - As of September 23, Zhenbaodao's stock price decreased by 2.09%, trading at 11.27 yuan per share, with a total market capitalization of 10.605 billion yuan. The stock has seen a decline of 1.57% year-to-date, 8.74% over the last five trading days, 11.05% over the last 20 days, and 3.18% over the last 60 days [1][2]. - The trading volume on September 23 was 17.7324 million yuan, with a turnover rate of 0.17%. The net inflow of main funds was 1.9645 million yuan, with significant buying activity from large orders [1]. Business Segmentation - The main business revenue composition includes: 84.82% from the sale of proprietary Chinese medicines, 7.13% from purchased medicinal materials, 5.11% from purchased pharmaceuticals, 2.51% from other sources, 0.35% from rental income, and 0.07% from interest income [2]. - Zhenbaodao is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine [2]. Shareholder Information - As of July 18, the number of shareholders for Zhenbaodao was 21,500, an increase of 2.34% from the previous period. The average circulating shares per person decreased by 2.29% to 43,744 shares [2].

中药材交易行业长期面临"小、散、乱"困境，规范化与现代化程度不足。传统交易依赖线下市场和个体 商户，信息不对称、价格机制不透明，致使药材价格差异大、品质参差不齐，影响用药安全与行业信 誉，制约产业高质量发展。 作为全国首家且安徽省唯一具备大宗中药材现货交易资质的亳州中药材商品交易中心(以下简称交易中 心)，历经5年市场调研与体系建设，于2025年国际(亳州)药博会期间正式启动"中药材大宗交易平台"升 级焕新，以多项突破性机制重塑行业生态。 中药材产业迎来标准化、金融化升级契机 近年来，《国务院办公厅关于印发"十四五"中医药发展规划的通知》等政策频出，从多维度引导行业规 模化、规范化、高质量发展。 在国家政策的大力推动下，中药材行业迎来新一轮发展机遇。亳州作为全国最大的中药材集散地，产业 模式的转型升级亦受到行业广泛关注。 中药材大宗交易平台率先推出仓单交易模式，实现药材标准化存管与便捷流转，并开设挂牌交易专场， 精准聚焦细分品种与特定交易场景，极大提升了交易效率与针对性。通过全流程线上化与电子仓单系 统，有效解决了传统现货交易中存在的效率低下、成本高昂及透明度不足等痛点，平台立足现货交收与 实体供应链建设，切 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 上市公司名称:黑龙江珍宝岛药业股份有限公司 股票上市地点:上海证券交易所 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通过任何其他方式增加或减少 其在黑龙江珍宝岛药业股份有限公司中拥有权益的股份。 股票简称：珍宝岛 股票代码：603567 信息披露义务人：黑龙江创达集团有限公司 住所/通讯地址：虎林市解放西街北检察院东侧宝润香林里1号楼1号门市 股份变动性质：股份减少 签署日期：2025年9月18日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第15号——权益变动报告书》等相关法律、法规和规范性文件编 制。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证券的公司信息披露内容与 格式准则第15号——权益变动报告书》的规定，本报告书已全面披露信息披露义务人在黑龙江珍宝岛药 业股份有限公司中拥有权益的股份变动情况。 四、本次权益变动是根据本报告书所载明的资料进行的。信息披 ...

黑龙江珍宝岛药业股份有限公司 简式权益变动报告书 上市公司名称:黑龙江珍宝岛药业股份有限公司 股票上市地点:上海证券交易所 股票简称：珍宝岛 股票代码：603567 信息披露义务人：黑龙江创达集团有限公司 住所/通讯地址：虎林市解放西街北检察院东侧宝润香林里1号楼1号门市 股份变动性质：股份减少 签署日期：2025年9月18日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》《上市公司收 购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动 报告书》等相关法律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 五、信息披露义务人保证本报告书及相关文件内容的真实性、准确性、完整性， 承诺其中不存在虚假记载、误导性陈述或重大遗漏，并就其保证承诺承担个别和连 带的法律责任。 1 | | | 释义 在本报告书中，除非另有说明，下列词语具有如下特定含义： | 公司、上市公司、珍宝岛 | 指 | 黑龙江珍宝岛药业股份有限公司 | | --- | --- | --- | | 信息披露义务人、创达集团 | 指 | 黑龙江创达集团有限公司 | | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次权益变动后，黑龙江创达集团有限公司（以下简称"创达集团"）持有黑 龙江珍宝岛药业股份有限公司（以下简称"公司"或"珍宝岛"）股份 563,334,314 股，占公司总股本的 59.87%。 本次权益变动属于创达集团发行的可交换公司债券持有人换股造成权益变动 人被动减持，不触及要约收购，不会导致公司控股股东及实际控制人发生变化。 一、本次权益变动基本情况 公司于近日收到控股股东创达集团的《简式权益变动报告书》，获悉创达集团发 行的 2023 年面向专业投资者非公开发行可交换公司债券（第一期）（以下简称"第 一期可交换债券"）和 2023 年面向专业投资者非公开发行可交换公司债券（第二期） （以下简称"第二期可交换债券"）的债券持有人发生换股，导致创达集团持股比例 被动下降，持有公司股份比例从 60.85%减少至 59.87%，跨越了 60%的刻度，现将本 次权益变动相关事项公告如下： 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-072 黑龙 ...

黑龙江珍宝岛药业股份有限公司发布控股股东权益变动提示性公告。自8月2日至9月18日，控股股东创 达集团发行的两期可交换债券换股9223963股，占总股本0.98%；截至9月18日累计换股16550986股，占 比1.76%。本次权益变动后，创达集团持股比例从60.85%降至59.87%，跨越60%刻度。此次变动系债券 持有人换股致其被动减持，不触及要约收购，不会使公司控股股东及实控人变化。公司将持续关注换股 事项并依规披露信息，提醒投资者注意风险。 ...

Group 1 - The core viewpoint of the news is that Zhenbaodao's stock has experienced fluctuations, with a recent decline in share price and significant net outflow of funds [1] - As of September 18, Zhenbaodao's stock price was 11.90 yuan per share, with a total market capitalization of 11.198 billion yuan [1] - The company has seen a year-to-date stock price increase of 3.93%, but a decline of 1.49% over the last five trading days and 6.08% over the last twenty days [1] Group 2 - Zhenbaodao's main business involves the research, production, and sales of high-end traditional Chinese medicine, with 84.82% of revenue coming from product sales [1] - The company reported a significant decrease in revenue for the first half of 2025, with a total of 714 million yuan, down 57.05% year-on-year, and a net profit loss of 78.29 million yuan, a decrease of 119.90% [2] - Since its A-share listing, Zhenbaodao has distributed a total of 1.302 billion yuan in dividends, with 356 million yuan distributed over the past three years [3]